Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment

Overview

Journal Cancer Res

Specialty Oncology

Date 2017 Apr 12

PMID 28396359

Citations 12

Authors

Lili Wang

Changying Shi

Forrest A Wright

Dandan Guo

Xu Wang

Dongliang Wang

Richard J H Wojcikiewicz

Juntao Luo

Affiliations

Soon will be listed here.

Abstract

We have developed multifunctional nanoparticles for codelivery of bortezomib and doxorubicin to synchronize their pharmacokinetic profiles and synergize their activities in solid tumor treatment, a need still unmet in the clinic. Micellar nanoparticles were formed by a spatially segregated, linear-dendritic telodendrimer containing three segments: a hydrophilic polyethylene glycol (PEG), a bortezomib-conjugating intermediate, and a dendritic doxorubicin-affinitive interior. Bortezomib-conjugated telodendrimers, together with doxorubicin, self-assembled into monodispersed micelles [NP(BTZ-DOX)] with small particle sizes (20-30 nm) for dual drug delivery. NP(BTZ-DOX) displayed excellent drug-loading capacity and stability, which minimized premature drug leakage and synchronized drug release profiles. Bortezomib release was accelerated significantly by acidic pH, facilitating drug availability in the acidic tumor microenvironment. Synergistic anticancer effects of combined bortezomib and doxorubicin were observed against both multiple myeloma and ovarian cancer cells. NP(BTZ-DOX) prolonged payload circulation and targeted tumors efficiently with superior signal ratios of tumor to normal organs. and proteasome inhibition analysis and biodistribution studies revealed decreased toxicity and efficient intratumoral bortezomib and doxorubicin delivery by nanoformulation. NP(BTZ-DOX) exhibited significantly improved ovarian cancer treatment in SKOV-3 xenograft mouse models in comparison with free drugs and their combinations, including bortezomib and Doxil. In summary, tumor-targeted and synchronized delivery system elicits enhanced anticancer effects and merits further development in the clinical setting. .

Citing Articles

Targeted Delivery of 5-Fluorouracil and Sonidegib via Surface-Modified ZIF-8 MOFs for Effective Basal Cell Carcinoma Therapy.

Padya B, Fernandes G, Hegde S, Kulkarni S, Pandey A, Deshpande P Pharmaceutics. 2023; 15(11).

PMID: 38004573 PMC: 10675485. DOI: 10.3390/pharmaceutics15112594.

Cisplatin and paclitaxel co-delivery nanosystem for ovarian cancer chemotherapy.

Wang Q, Wu C, Li X, Yang D, Shi L Regen Biomater. 2022; 8(3):rbab015.

PMID: 35707698 PMC: 8240646. DOI: 10.1093/rb/rbab015.

Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases.

Mohamed N, Marei I, Crovella S, Abou-Saleh H Int J Mol Sci. 2022; 23(3).

PMID: 35163328 PMC: 8836006. DOI: 10.3390/ijms23031404.

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer.

Bi J, Zhang Y, Malmrose P, Losh H, Newtson A, Devor E Cell Death Dis. 2022; 13(1):59.

PMID: 35039480 PMC: 8763941. DOI: 10.1038/s41419-022-04508-2.

Nanoparticulation of Prodrug into Medicines for Cancer Therapy.

Zhang Y, Cui H, Zhang R, Zhang H, Huang W Adv Sci (Weinh). 2021; 8(18):e2101454.

PMID: 34323373 PMC: 8456229. DOI: 10.1002/advs.202101454.

References

Gatti L, Zuco V, Zaffaroni N, Perego P . Drug combinations with proteasome inhibitors in antitumor therapy. Curr Pharm Des. 2012; 19(22):4094-114. DOI: 10.2174/1381612811319220015. View

Bruning A, Burger P, Vogel M, Rahmeh M, Friese K, Lenhard M . Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Invest New Drugs. 2008; 27(6):543-51. DOI: 10.1007/s10637-008-9206-4. View

Swami A, Reagan M, Basto P, Mishima Y, Kamaly N, Glavey S . Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A. 2014; 111(28):10287-92. PMC: 4104924. DOI: 10.1073/pnas.1401337111. View

Xu Q, Farah M, Webster J, Wojcikiewicz R . Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ubiquitination of histones and type I inositol 1,4,5-trisphosphate receptor. Mol Cancer Ther. 2004; 3(10):1263-9. View

Kratz F, Warnecke A . Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems. J Control Release. 2012; 164(2):221-35. DOI: 10.1016/j.jconrel.2012.05.045. View

Woodcock J, Griffin J, Behrman R . Development of novel combination therapies. N Engl J Med. 2011; 364(11):985-7. DOI: 10.1056/NEJMp1101548. View

Yang C, Gonzalez-Angulo A, Reuben J, Booser D, Pusztai L, Krishnamurthy S . Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol. 2006; 17(5):813-7. DOI: 10.1093/annonc/mdj131. View

Huang Z, Wu Y, Zhou X, Xu J, Zhu W, Shu Y . Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncol. 2014; 10(10):1795-807. DOI: 10.2217/fon.14.30. View

Matsumura Y, Maeda H . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46(12 Pt 1):6387-92. View

10.

Tannock I, Rotin D . Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989; 49(16):4373-84. View

11.

Wang X, Bodman A, Shi C, Guo D, Wang L, Luo J . Tunable Lipidoid-Telodendrimer Hybrid Nanoparticles for Intracellular Protein Delivery in Brain Tumor Treatment. Small. 2016; 12(31):4185-92. PMC: 4982832. DOI: 10.1002/smll.201601234. View

12.

Foley O, Rauh-Hain J, Carmen M . Recurrent epithelial ovarian cancer: an update on treatment. Oncology (Williston Park). 2013; 27(4):288-94, 298. View

13.

Orlowski R, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A . Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007; 25(25):3892-901. DOI: 10.1200/JCO.2006.10.5460. View

14.

Wheat L, Kohlhaas S, Monbaliu J, De Coster R, Majid A, Walewska R . Inhibition of bortezomib-induced apoptosis by red blood cell uptake. Leukemia. 2006; 20(9):1646-9. DOI: 10.1038/sj.leu.2404290. View

15.

Li Y, Xiao W, Xiao K, Berti L, Luo J, Tseng H . Well-defined, reversible boronate crosslinked nanocarriers for targeted drug delivery in response to acidic pH values and cis-diols. Angew Chem Int Ed Engl. 2012; 51(12):2864-9. PMC: 3545653. DOI: 10.1002/anie.201107144. View

16.

Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D . An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. Int J Gynecol Cancer. 2012; 22(5):792-800. DOI: 10.1097/IGC.0b013e318251051a. View

17.

Gillet J, Gottesman M . Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 2009; 596:47-76. DOI: 10.1007/978-1-60761-416-6_4. View

18.

Thamake S, Raut S, Gryczynski Z, Ranjan A, Vishwanatha J . Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials. 2012; 33(29):7164-73. DOI: 10.1016/j.biomaterials.2012.06.026. View

19.

Lee H, Fonge H, Hoang B, Reilly R, Allen C . The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm. 2010; 7(4):1195-208. DOI: 10.1021/mp100038h. View

20.

Gottesman M . Mechanisms of cancer drug resistance. Annu Rev Med. 2002; 53:615-27. DOI: 10.1146/annurev.med.53.082901.103929. View